Our mission at iTeos is to discover and develop immune therapies to benefit people with cancer. Immunotherapy is a breakthrough approach in the treatment of cancer that seeks to educate the immune system to recognize and eliminate the tumor. The first generation of immunotherapies, including immune checkpoint inhibitors and cancer vaccines, have been limited by the proportion of patients who benefit, and by the depth and duration of response in those who do. Therapeutic benefit has been observed in tumors invaded by T-cells, the so-called inflamed, immunogenic, or "hot" tumors.
Even in "hot" tumors, potent immunosuppressive mechanisms dampen T cell activity and limit the efficacy of checkpoint inhibitors. These immunosuppressive mechanisms have been targeted by iTeos’ first wave of programs, using both small molecules and biologics.
Building on strong drug discovery and early clinical development expertise, iTeos will determine the clinical efficacy of its approaches in proof of concept trials, on its own or in co-development with partners. iTeos is also developing methods to identify unique combinations of therapeutics to demonstrate clinical efficacy in selected cancer indications and achieve regulatory approval on its own.